GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Cyclically Adjusted Price-to-FCF

Nymox Pharmaceutical (Nymox Pharmaceutical) Cyclically Adjusted Price-to-FCF : (As of May. 02, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nymox Pharmaceutical Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Cyclically Adjusted Price-to-FCF Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.



Nymox Pharmaceutical Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Nymox Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Nymox Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.014/129.8595*129.8595
=-0.014

Current CPI (Sep. 2023) = 129.8595.

Nymox Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -0.043 98.326 -0.057
201403 -0.040 99.695 -0.052
201406 -0.040 100.560 -0.052
201409 -0.045 100.428 -0.058
201412 -0.031 99.070 -0.041
201503 -0.011 99.621 -0.014
201506 -0.024 100.684 -0.031
201509 -0.030 100.392 -0.039
201512 -0.034 99.792 -0.044
201603 -0.037 100.470 -0.048
201606 -0.015 101.688 -0.019
201609 -0.014 101.861 -0.018
201612 -0.031 101.863 -0.040
201703 -0.015 102.862 -0.019
201706 -0.034 103.349 -0.043
201709 -0.046 104.136 -0.057
201712 -0.023 104.011 -0.029
201803 -0.032 105.290 -0.039
201806 -0.032 106.317 -0.039
201809 -0.039 106.507 -0.048
201812 -0.026 105.998 -0.032
201903 -0.024 107.251 -0.029
201906 -0.031 108.070 -0.037
201909 -0.027 108.329 -0.032
201912 -0.026 108.420 -0.031
202003 -0.030 108.902 -0.036
202006 -0.030 108.767 -0.036
202009 -0.054 109.815 -0.064
202012 -0.022 109.897 -0.026
202103 -0.034 111.754 -0.040
202106 -0.023 114.631 -0.026
202109 -0.036 115.734 -0.040
202112 -0.027 117.630 -0.030
202203 -0.049 121.301 -0.052
202206 0.015 125.017 0.016
202209 -0.014 125.227 -0.015
202212 -0.014 125.222 -0.015
202303 -0.011 127.348 -0.011
202306 -0.010 128.729 -0.010
202309 -0.014 129.860 -0.014

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nymox Pharmaceutical  (OTCPK:NYMXF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Nymox Pharmaceutical Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

May 2023 Market Cap Requirement Update

By GlobeNewswire GlobeNewswire 11-25-2022

NYMOX Announces New Marketing Submission for NYMOZARFEX� for BPH

By Value_Insider Value_Insider 12-05-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023